Rationale: There are no risk stratification tools for morbidity and mortality in bronchiectasis.
Identifying patients at risk of exacerbations, hospital admissions, and mortality is vital for …

Purpose Airways remodeling, evaluated as the subepithelial layer thickness, was compared
in asthmatic patients with that of healthy subjects, and was related to clinical grading of …

Rationale: Testing for underlying etiology is a key part of bronchiectasis management, but it
is unclear whether the same extent of testing is required across the spectrum of disease …

Background: Churg-Strauss syndrome (CSS) is a rare disorder characterized by asthma,
eosinophilia, and systemic vasculitis. Renal involvement is not regarded as a prominent feature…

Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups
of patients with different clinical and biological characteristics and long-term outcomes. This …

In a double-blind, parallel-group study, we examined the effect of short-term treatment with
inhaled fluticasone propionate (FP) in a group of 20 nonsmoking asthmatic patients who …

Background Since 2009, IPF patients across Europe are recruited into the eurIPFreg, providing
epidemiological data and biomaterials for translational research. Methods The registry …

Background Patients with bronchiectasis often have concurrent comorbidities, but the nature,
prevalence, and impact of these comorbidities on disease severity and outcome are poorly …

Background: Cysteinyl leukotrienes (Cys-LTs) and isoprostanes are inflammatory metabolites
derived from arachidonic acid whose levels are increased in the airways of asthmatic …

Nitrosothiols (RS-NOs) are formed by interaction of nitric oxide (NO) with glutathione and
may limit the detrimental effect of NO. Because NO generation is increased in airway …